Hi everyone,
I opened a vocabulary proposal on GitHub for a use case I haven’t seen addressed in OMOP: therapeutic peptides used in compounding pharmacies and the gray market.
Compounds like BPC-157, TB-500, ipamorelin, sermorelin, and cerebrolysin have no NDC codes, no RxNorm entries, and no OMOP concept identifiers — making them invisible to any CDM-based pharmacovigilance analysis.
I identified 173 FAERS reports across 6 of these compounds, with seriousness rates up to 100% and cerebrolysin showing 15 deaths in 75 cases. These signals exist but cannot be studied in OMOP today.
The proposal covers 12 compounds with CAS/ChEMBL anchoring and maps_to RxNorm for the two FDA-approved compounds (tesamorelin, bremelanotide).
Timing context: the FDA advisory panel is meeting in July 2026 to review peptide compound safety — vocabulary infrastructure would enable the community to contribute evidence to that process.
GitHub issue with full details: New vocabulary proposal: PEPTIDE_LOCAL — OMOP CDM vocabulary for therapeutic peptides without NDC/RxNorm coverage · Issue #1255 · OHDSI/Vocabulary-v5.0 · GitHub
A few specific questions for the Vocabulary team:
- Is “Peptide Ingredient” an acceptable concept_class_id, or should these map to an existing class?
- What concept_id namespace is safe for local vocabularies?
- Should standard_concept be ‘C’ or NULL for non-approved compounds?
Appreciate any feedback. Happy to present at a future Vocabulary WG call if useful.
Igor Eduardo
Eterna Research, Austin, TX
ORCID: 0009-0005-6288-1135